Pfizer CEO expects Trump to eliminate drug rebates

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/17/2026

1. VRNS
2. JBHT
3. CRWV
4. TSLA
5. SCHW
6. GPRK
7. TFC
8. TRV
9. USB
10. SPY

Go back to Pfizer CEO expects Trump to eliminate drug rebates

Pfizer (PFE) Reports Marketing Authorization in European Union from Euro Commission for Moderately to Severely Active Ulcerative Colitis

August 1, 2018 6:30 AM EDT

Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has approved XELJANZ® (tofacitinib citrate) 10 mg twice-daily (BID) for at least eight weeks, followed by XELJANZ 5 mg BID or 10 mg BID, for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.1 XELJANZ is the first and only oral therapy and Janus kinase (JAK) inhibitor to be approved for this patient population.

In approving XELJANZ for UC, the European Medicines... More